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Background: Following high-profile device failures, the Heart Rhythm Society emphasized the need
for postmarketing surveillance by recommending that physicians return all explanted devices to the
manufacturer for analysis.
Methods: We conducted a national survey of electrophysiologists (EPs) regarding recovery for analysis of
explanted pacemakers and implantable cardioverter defibrillators (devices), and attitudes toward device-
specific advance directives to facilitate return of devices. Online survey invitations were sent in four
waves from December 2008 to June 2009 to 300 e-mail addresses from the Heart Rhythm Society member
database.
Results: From 250 invitations, there were 95 responses (38%). Demographics included average age
50 years (range, 31–87); 95% male; 81% Caucasian. Only 23% reported returning all explanted devices
to the manufacturers. Of all the respondents, 32% discarded >10 devices/year as medical waste, 42%
stored devices in a box in the electrophysiology lab, and 10% donated at least 1 device/year to charity
for reuse overseas. Sixty-seven percent felt that it would not be helpful to have an advance directive
specifying what the patient would want done with their device postmortem.
Conclusions: Few EPs return all explanted devices or send interrogation reports to the manufacturers,
though nearly all said it was easy to do so. A majority either dispose of explanted devices as medical
waste or store them in laboratories or offices, and a small percentage donate for reuse in underserved
nations or to veterinary hospitals. This study suggests a need for initiatives such as educational
campaigns to increase the retrieval and return of devices, either for analysis or reuse. (PACE 2011;
34:659–665)
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Introduction
Following a series of pacemaker (PPM) and
defibrillator (ICD) recalls and extensive press cove-
rage of device failures, the Heart Rhythm Society
(HRS) in 2006 recommended the establishment of
device performance policies and guidelines appli-
cable to physicians, governmental agencies, and
manufacturers. Millions of pacemaker and ICD im-
plants are used worldwide, and there is a general
perception that these devices are safe. However,
aside from industry-sponsored testing, there are
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few independent data on long-term reliability.1 In
its report following the device failures, the HRS
emphasized the need for postmarketing survei-
llance by recommending that physicians return all
explanted devices to the manufacturer for analysis
in order to improve the reporting of device mal-
function and enhance patient safety.2 In addition,
the report called for the establishment of a legally
binding device advance directive that would allow
for postmortem device removal and interrogation.
Postmortem device retrieval requires cooperation
between manufacturers and governmental agen-
cies but also patients, physicians, and funeral
directors. The current literature suggests that even
though patients and funeral directors are willing
to participate in postmortem device retrieval,
devices are often thrown away or kept in the
funeral home.3 Besides return to the manufacturer,
explanted devices can also be donated to charities
for reuse in underdeveloped nations, or to
veterinary hospitals for reuse in animals.
In this study, we describe how electrophysiol-
ogists (EPs) report handling devices postexplant,
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and we outline their opinions on device advance
directives, postmortem device retrieval and inter-
rogation, and return of device to the manufacturer
or for charitable reuse.
Methods
We conducted a national survey of EPs.
From December 2008 to June 2009, online survey
invitations were sent in four separate waves to
300 e-mail addresses taken from the HRS member
database. A total of 32 subjects identified as
basic scientists, pediatric EPs, nonimplanting EPs,
or retired EPs were excluded, whereas 18 e-
mails were not deliverable. To the remaining
250 invitations, there were 95 responses (re-
sponse rate 38%). The survey included multiple
choice, yes/no, Likert scale, and short answer
questions. In addition to demographic data, the
questions sought information on the number of
device implants and explants performed every
year, preexplant device interrogation, explanted
device destination, and problems encountered in
returning explanted devices to manufacturers. In
addition, we queried opinions regarding advance
directives, which would indicate patients’ prefe-
rences regarding postmortem device disposition
(See Appendix S1).
Results
The average age of the participants was
50 years (range, 31–87 years); 95% of the
participants were male; 81% were Caucasian, 11%
Asian, and 5% Hispanic; 62% had an academic
affiliation; 70% were from urban areas, 25% from
suburban areas, and 5% from rural areas. The
surveyed EPs performed 98 ± 75 device implants
and 44 ± 40 explants per year, including generator
changes and upgrades (Table I).
With respect to postmortem device disposi-
tion, only 23% of the total respondents reported
returning all explanted devices to the manufac-
turers, though 92% believed it was easy or very
easy to do so. Only 14% of respondents reported
barriers to returning devices to the manufacturers,
whereas 55% felt that it would be easy or very
easy to return devices to a central agency, which
would interrogate each device and forward it to
the appropriate manufacturer. Of those returning
all devices to the manufacturers, 76% practiced in
an urban setting, 14% in a suburban setting, and
10% in a rural setting.
Of all the respondents, 32% discarded >10
devices/year as medical waste, 42% stored devices
in a box in the electrophysiology lab or office,
and 10% donated at least one device/year to
charity for reuse overseas (Table II). When asked
about who should have the most influence in
determining what happens to a device after it is
Table I.
Characteristics of Surveyed Electrophysiologists
Characteristic Value
Age, years, median (range) 50 (31–87)
Male, % 95









Estimated procedures per year
Device implants 98 ± 75
Device explants 44 ± 40
Table II.
Disposition of Devices Explanted by Electrophysiologists
Percentage of
Response Respondents
Decisions about explanted devices
Discarded >10 devices/year as
medical waste
32
Stored devices in lab/office 42
Donated at least 1/year to charity
for reuse overseas
10
Returned devices to manufacturer 23
Easy or very easy to return
devices to manufacturer
92





explanted, 38% of the respondents said it was the
explanting physician (Table III). A majority, 67%,
felt that it would not be helpful for patients to
write an advance directive specifying the patient’s




The use of ICDs and PPMs has resulted
in improved survival in patients with certain
cardiac conditions.4 However, mortality rates in
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Table III.
Postexplant Device Disposition
Who Has the Most Say




Patient or family 13
The Food and Drug Administration 12
Insurance company or medicare 2
Other 16
these patients remain high as they often succumb
to progressive cardiac disease or noncardiac
comorbidities. With the increase in the use of ICDs
and PPMs, questions have been raised regarding
the proper handling of these devices at the end
of a patient’s life. In the past, device recalls
have brought national attention to the safety and
reliability of these devices. Despite the increasing
number of implants used worldwide, a wide array
of indications for implantation, and the increasing
complexity of the ICDs and PPMs, the overall
reliability of these devices is not well defined.5
Although device malfunction rates are estimated
to be low, the clinical consequences of device
malfunction can be substantial. Since patients
requiring such devices usually have multiple
comorbidities, the precise cause of death—device
malfunction, progression of underlying disease,
or some other factor—sometimes cannot be
ascertained without a postmortem examination.
Autopsies involve visual inspection of devices and
leads but often do not involve device interrogation
or bench testing.
The manufacturers of devices are legally obli-
gated to notify the Food and Drug Administration
(FDA) about any device malfunction that has
resulted in or may result in harm to a patient.
When a manufacturer reports a malfunction, the
FDA may require the manufacturer to notify the
medical community or even to pull the device
in question off the market. Hospital entities
are legally required to notify the FDA of life-
threatening device malfunctions under the Safe
Medical Devices Act of 2006.6 It can be argued
that clinicians, though not legally responsible for
reporting device malfunctions, do have an ethical
responsibility to alert authorities and the manufac-
turers of malfunctions. However, underreporting
of device malfunction by the clinical community
as a whole has made it difficult to accurately
determine the device-malfunction rate.7
The present study suggests that few EPs return
explanted devices or send interrogation reports to
the manufacturers after a patient’s death, though
nearly all feel that it is not difficult to do so.
This discrepancy may have to do with a low
priority placed on device retrieval. EPs may be
more focused on the welfare of their patients, not
of the devices or future recipients of newer device
models. It can be argued, however, that returning
suspect devices, if not all devices, may uncover
defects in a current patient’s device model, which
may lead to more frequent device checks, if
not generator replacement. Analysis of returned
devices may improve future models in which
the same malfunctioning component or circuit
design is used. Serious malfunctions may present
intermittently. These returns, therefore, should be
accompanied by as much information as possible
(rhythm strips, printouts, stored electrograms, and
anything else that may demonstrate abnormal
behavior) to help guide the manufacturer in the
evaluation of the returned devices.
Lack of unbiased feedback to physicians from
manufacturers about the procedures used to exa-
mine devices and the results of these examinations
may also contribute to a lack of motivation to
return devices. One major manufacturer reports
communicating the results of analysis in writing
to the explanting physician only if the analysis
reveals a malfunction, if there is a suspected
performance issue with the device, or if the physi-
cian requests such communication (Rapallini L.
September 8, 2010, Personal Communication).
Device company representatives are also not
incentivized to encourage the return of devices.
In addition, there may not be adequate physician
education concerning the recommendation to
return all devices.
It should be noted that the survey asked
about EPs’ experiences, not whether they believed
that all potentially retrievable devices can be
easily obtained. Clearly, multiple barriers exist
to acquisition of all explanted devices, especially
for postmortem retrieval (or even interrogation) of
devices from morgues and funeral homes, such as
lack of a universal programmer capable of ana-
lyzing all device models and inadequate interface
between the electrophysiology community and the
funeral industry.
Although not suggested by our data (in
which the plurality of EPs thought the explanting
physician had the most influence over device des-
tination), concerns regarding patient or next of kin
consent to return devices play a role. Other survey
studies suggest that a majority of funeral directors
believe that postmortem device retrieval and
interrogation are feasible,3 but that unauthorized
postmortem removal of a device without written
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consent from the patient constitutes a breach
of professional conduct.8 The HRS recommends
that physicians seek patients’ consent while they
are alive for postmortem return of all explanted
devices to the manufacturer for analysis, but few
physicians discuss end of life consideration of
devices with patients who are dying.9 Few EPs
in our study supported the idea of an advance
directive by which patients outline what they want
done with devices postexplant. These findings are
in contrast to patient survey responses, which
indicate that most patients are willing to sign
device advance directives authorizing postmortem
device retrieval and interrogation.3 It can be
speculated that time constraints may, in part, be
responsible for the lack of support for advance
directives by EPs. It may be feasible to have other
health care professionals, such as nurses, play a
more active role in obtaining patient consent for
postmortem analysis of devices.
Procedures for Return and Analysis
All major manufacturers provide instructions
and mailer kits on their websites for return
of devices.10–12 Devices can also be handed to
company representatives who are often present
in EP labs. Once an explanted device is returned
to the manufacturer, return product analysis
is performed to determine if the device has
malfunctioned or has reached normal battery
depletion. Whether additional bench testing is
performed on devices suspected of malfunction
depends on the results of initial testing. Each
manufacturer is required to establish internal
standards for testing procedures that are reviewed
and approved by the FDA. Currently, however, the
International Standards Organization has set no
global standards of evaluation of returned devices.
According to a company official at Medtronic
Inc., approximately 1,800 devices are returned
each week for analysis.13 The company official we
contacted declined to comment on the financial
costs related to this analysis. Based on Centers for
Medicare and Medicaid Services (CMS) data, the
payment for interrogation and analysis of a single-
or dual-lead ICD is $70.06.14 Using these numbers,
the cost related to interrogating devices returned to
a single major manufacturer appears to be at least
$126,000 per week, but the actual number is likely
much higher. Manufacturers are not reimbursed
by CMS for postexplant evaluation of a device.
The true costs to the manufacturer depend on the
amount of work performed to identify potential
problems, which may involve considerably more
effort than standard programmer interrogation and
analysis.
The data extracted from returned devices
are used to estimate device survival probability
that predicts the length of time over which the
product is expected to perform within perfor-
mance limits established by the manufacturer.
All five major manufacturers publish such data
on their websites.15–19 However, most of the
testing is performed on devices returned as a
result of explant before death, and it is not clear
whether devices routinely explanted after death
constitute a similar or different population. Return
of all explanted devices, regardless of the reason
for explant, will likely lead to more accurate
device survival estimates that are reflective of
the entire population of devices. It may be that
inclusion of devices explanted postmortem will
lead to calculation of a higher survival probability,
but they may also reveal malfunctions that may
have contributed to patient death. Furthermore,
analysis of these returned devices would reveal
the magnitude of inadvertent turn-off of devices
caused by poor programming or exposure to
electromagnetic energy sources.
The majority of EPs in our sample thought
the current ways to return devices were facile.
A slim majority thought that it would also be
easy to return devices via a central agency that
would collect devices and then forward them to
the appropriate manufacturers. Our data therefore
do not suggest that device return would be
significantly increased by creation of a central
agency. The advantage of a central agency would
seem to lie in the independent and unbiased
analysis of devices, but creation of such an
entity would be hampered by the need for large
amounts of funding required for safe handling
and analysis of returned devices. Industry, in
all likelihood, would be reluctant to provide the
necessary funding and would certainly pass the
cost along to consumers. The government may be
in a position to contribute funds; however, such a
proposal would probably be politically unpopular
during a cost-conscious time. It may be possible
to administer a central agency under AdvaMed,
an industry-funded medical device manufacturer
trade group which has, as part of its mission
statement, the promotion of compliance with
ethical standards. In addition, the manufacturers
are unlikely to share proprietary software and
design features with an outside agency. More
reliable cost-estimates and pilot studies are
necessary to justify the cost-effectiveness and
feasibility of a central agency.
Remote ICD monitoring and wireless interro-
gation has the potential to make postmortem de-
vice interrogation from hospitals, funeral homes,
morgues, and other remote venues more feasible.
According to the Heart Rhythm Society Task
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Force on Device Performance Policies Guidelines,
the primary goal of remote ICD monitoring is to
limit underreporting of device malfunctions.2 In
addition, remote device monitoring may allow for
easier management of reused devices overseas in
developing nations.
Leads
Although the current study focuses on the
return of explanted PPMs and ICDs to manufactur-
ers, lead malfunction remains a dominant cause
of system dysfunction.20 The FDA recommends
that all leads and lead fragments removed from
the body be returned to the manufacturer for
analysis.21 While malfunctioning leads are usually
capped and left in the body predeath, except
in cases of infection, after death they can
be explanted along with the pulse generator.
Postmortem lead extraction (if performed en
bloc with careful dissection) and return to the
manufacturers may play a significant future role
in product improvement. Lead extraction is
often a technically difficult procedure. Progressive
fibrosis and adherence of the lead body to the
myocardium and venous endothelium may result
in partial extraction or lead damage during the
extraction process, rendering the lead virtually
unusable for analysis. Pathologists and morticians
who are extracting devices should attempt to
remove the leads within the vascular system and
heart as a block, then carefully dissect out the
leads.
Device Donation
In addition to return to the manufacturers,
there are other options for postmortem device
handling. A small number of EPs in our sample
donated explanted devices to charitable organi-
zations that interrogate and sterilize the devices,
which are then reimplanted in patients in develo-
ping nations. In recent decades, the morbidity and
mortality associated with cardiovascular disease
has steadily declined in industrialized nations
due to technological innovations and widespread
access to healthcare.22 However, cardiovascular
disease remains the leading cause of death in low-
and middle-income countries.23 In these develo-
ping countries, the cost of devices such as PPMs
and ICDs may be the most important limiting
factor for patients who require them.24 Therefore,
PPM reuse, the safety and efficacy of which has
been reasonably well documented,25–27 would
appear to be a promising solution. ICD reuse is
more complicated and may not be advisable.28
This situation may be advantageous for patients
in low- and middle-income countries with limited
access to expensive healthcare. Devices may also
be donated to veterinary hospitals for use in
animals.3
Improving Postmortem Device Retrieval
Though the 2006 HRS document outlined the
problem and proposed a number of initiatives,
it did not appear to affect the practice of the
majority of EPs in our sample (surveyed several
years after its publication). Our data suggest that
more targeted educational campaigns by profes-
sional organizations directed toward physicians
(and funeral directors) may be necessary. These
endeavors could detail the importance of return
or reuse of devices and may increase the number
of devices retrieved for product improvement
analysis and for donation to charities. A simple
form which presents the various options for device
and lead destination after explant, presented at
the time of device implant or during follow-up,
may involve patients in the process (see Appendix
S2). The timing of presentation of this form
to patients may be crucial. If presented at the
time of implantation, symptomatic patients may
feel pressured to sign. On the other hand, less
symptomatic patients may not be very motivated
to sign a legally binding document permitting
postmortem explant, resulting in excess refusals.
Ideally, the document should be presented to
the patient during the follow-up period shortly
after implantation. Alternatively, this document,
consisting of a short form, may be presented at
the time of device implantation and sent home
with the patient for thoughtful consideration,
to be brought back at the initial follow-up
visit. Included in the form can be an advance
directive discussing specific issues related to
device deactivation at the end of life, as suggested
by a recent HRS consensus statement.29 This
document should be given the same legal standing
as more generalized advance directives.30 Specific
guidelines outlining how to dialogue with patients
concerning postmortem device disposition may be
necessary.
Manufacturers of ICDs and PPMs should
continue to encourage the return of explanted
devices for analysis. Company representatives
should be incentivized by manufacturers to
encourage return of all explanted devices, in-
cluding those with no known malfunctions. In
addition, manufacturers should provide device
representatives with preaddressed mailers for
distribution to EPs rather than depending on
the EPs to obtain mailers from the company
website. Manufacturers, via their representatives
and via sponsored events at national and regional
meetings, can also educate physicians and allied
health professionals about returning explanted
devices. During educational sessions, physicians
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and allied health professionals should be re-
minded of the wider public health issues involved
and the potential benefits of explanted device
analysis for future patients. An HRS- or FDA-
sponsored award for returning explanted devices
may serve as an incentive for physicians and
institutions.
Upon completion of analysis of returned
devices, manufacturers should provide physicians
with detailed feedback, possibly by sending
quarterly or semiannual e-mail reports of the
analyses performed in a given time period to all
HRS members, in addition to individual letters
(Appendices S3 and S4).
In addition to relying on device repre-
sentatives for returns, hospitals and funeral
homes should formulate institutional policies that
encourage returning explanted devices to the
manufacturers. In cases where return of all devices
from hospitals, morgues, and funeral homes is
not feasible, return of a preplanned fraction of
all explanted devices may serve as a semirandom
sample for interrogation and bench testing. The
returning source should be encouraged to include
relevant clinical data with the returned device
including presence or absence of suspected mal-
function. Devices without suspected malfunction
may undergo a simplified screening evaluation by
the manufacturer, with further testing performed
only if the initial evaluation is concerning for
device malfunction.
Study Limitations
The generalizability of this study is limited by
its response rate, and the lack of diversity in the
gender and ethnicity of the survey responders. As
with any survey relying on response to invitations,
there may have been a self-selection bias. EPs were
asked to recollect numbers from memory, and we
did not have records to verify the accuracy of these
numbers.
Conclusions
Few EPs return explanted devices or send
interrogation reports to manufacturers, though
nearly all believe that both may be possible. A ma-
jority of the EPs dispose of the explanted devices
in medical waste or store them in laboratories
or offices, and a small percentage donate them
for reuse in underserved nations or to veterinary
hospitals. This study suggests a need for initiatives
to increase the retrieval and return of devices,
either for analysis or reuse. Such initiatives might
include educational campaigns by professional
societies and manufacturers, patient advance
directives to authorize retrieval of devices for
analysis and/or reuse, incentivization of company
device representatives and, perhaps, clinicians,
and timely, unbiased feedback to physicians. In
addition, wireless remote interrogation, especially
in funeral homes and morgues, may have a role in
limiting underreporting of device malfunction in
the future.
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